Rahul Roychoudhuri

Rahul Roychoudhuri

Auto-generated profile, based on publicly available information

Rahul Roychoudhuri

Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2013 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MSMadhusudhanan Sukumar
Madhusudhanan Sukumar
JLJie Liu
Jie Liu
YJYun Ji
Yun Ji
MSMurugan Subramanian
Murugan Subramanian
JCJoseph G. Crompton
Joseph G. Crompton
LGLuca Gattinoni
Luca Gattinoni
Naive CD8+ T cells rely upon oxidation of fatty acids as a primary source of energy. After antigen encounter, T cells shift to a glycolytic metabolism to sustain effector function. It is unclear, however, whether changes in glucose metabolism ultimately influence the ability of activated T cells to become long-lived memory cells. We used a fluorescent glucose analog, 2-NBDG, to quantify glucose uptake in activated CD8+ T cells. We found that cells exhibiting limited glucose incorporation had a molecular profile characteristic of memory precursor cells and an increased capacity to enter the memory pool compared with cells taking up high amounts of glucose. Accordingly, enforcing glycolytic metabolism by overexpressing the glycolytic enzyme phosphoglycerate mutase-1 severely impaired the ability of CD8+ T cells to form long-term memory. Conversely, activation of CD8+ T cells in the presence of an inhibitor of glycolysis, 2-deoxyglucose, enhanced the generation of memory cells and antitumor functionality. Our data indicate that augmenting glycolytic flux drives CD8+ T cells toward a terminally differentiated state, while its inhibition preserves the formation of long-lived memory CD8+ T cells. These results have important implications for improving the efficacy of T cell–based therapies against chronic infectious diseases and cancer.

14 September 2016 in Nature
Verified
Journal Article
Open access
PDF file
RERobert Eil
Robert Eil
SVSuman K. Vodnala
Suman K. Vodnala
DCDavid Clever
David Clever
CKChristopher A. Klebanoff
Christopher A. Klebanoff
MSMadhusudhanan Sukumar
Madhusudhanan Sukumar
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo
Potassium ions released by necrotic cells in tumours impair T cell function by increasing the intracellular potassium concentration in vitro and in vivo. Cell death in tumours is frequently associated with a poor prognosis, a phenomenon that has previously been attributed to rapidly dividing cancer cells in a resource-limited environment. Robert Eil et al. demonstrate that intratumoural cell death in fact plays an active part in suppressing anti-tumour immunity. They show that elevated extracellular potassium in human and mouse tumour interstitial fluid inhibits T-cell-receptor-induced anti-tumour functions in human and mouse T cells. In addition, this immune suppression can be reversed by enabling tumour-specific T cells to efflux potassium through overexpression of the exporter Kcna3. Tumours progress despite being infiltrated by tumour-specific effector T cells1. Tumours contain areas of cellular necrosis, which are associated with poor survival in a variety of cancers2. Here, we show that necrosis releases intracellular potassium ions into the extracellular fluid of mouse and human tumours, causing profound suppression of T cell effector function. Elevation of the extracellular potassium concentration ([K+]e) impairs T cell receptor (TCR)-driven Akt–mTOR phosphorylation and effector programmes. Potassium-mediated suppression of Akt–mTOR signalling and T cell function is dependent upon the activity of the serine/threonine phosphatase PP2A3,4. Although the suppressive effect mediated by elevated [K+]e is independent of changes in plasma membrane potential (Vm), it requires an increase in intracellular potassium ([K+]i). Accordingly, augmenting potassium efflux in tumour-specific T cells by overexpressing the potassium channel Kv1.3 lowers [K+]i and improves effector functions in vitro and in vivo and enhances tumour clearance and survival in melanoma-bearing mice. These results uncover an ionic checkpoint that blocks T cell function in tumours and identify potential new strategies for cancer immunotherapy.

30 January 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
AHAmanda N. Henning
Amanda N. Henning
RRRahul Roychoudhuri
Rahul Roychoudhuri
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo

1 December 2011 in Immunity
Verified
Journal Article
Closed access
PMPawel Muranski
Pawel Muranski
ZBZachary A. Borman
Zachary A. Borman
SKSid P. Kerkar
Sid P. Kerkar
CKChristopher A. Klebanoff
Christopher A. Klebanoff
YJYun Ji
Yun Ji
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo

2 June 2013 in Nature
Verified
Journal Article
Open access
PDF file
RRRahul Roychoudhuri
Rahul Roychoudhuri
KHKiyoshi Hirahara
Kiyoshi Hirahara
KMKambiz Mousavi
Kambiz Mousavi
DCDavid Clever
David Clever
CKChristopher A. Klebanoff
Christopher A. Klebanoff
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo
Diverse autoimmune and allergic diseases are associated with polymorphisms in a locus encoding the transcription factor BACH2; here, BACH2 is shown to be a broad regulator of immune activation that stabilizes the differentiation of Treg cells by repressing commitment of CD4+ T cells to alternate cell fates. Polymorphisms within a locus encoding the transcription factor BACH2 are associated with a number of allergic and autoimmune diseases including asthma, multiple sclerosis, Crohn's disease, coeliac disease and type 1 diabetes. This paper identifies a mechanism by which BACH2 might contribute to autoimmunity. Roychoudhuri et al. show how BACH2 limits autoimmunity by repressing alternative cell fates through the stabilization of the differentiation of regulatory T cells. These findings suggest a role for BACH2 as a regulator of CD4+ T-cell differentiation, preventing inflammatory disease by controlling the balance between tolerance and immunity. Through their functional diversification, distinct lineages of CD4+ T cells can act to either drive or constrain immune-mediated pathology. Transcription factors are critical in the generation of cellular diversity, and negative regulators antagonistic to alternate fates often act in conjunction with positive regulators to stabilize lineage commitment1. Genetic polymorphisms within a single locus encoding the transcription factor BACH2 are associated with numerous autoimmune and allergic diseases including asthma2, Crohn’s disease3,4, coeliac disease5, vitiligo6, multiple sclerosis7 and type 1 diabetes8. Although these associations point to a shared mechanism underlying susceptibility to diverse immune-mediated diseases, a function for BACH2 in the maintenance of immune homeostasis has not been established. Here, by studying mice in which the Bach2 gene is disrupted, we define BACH2 as a broad regulator of immune activation that stabilizes immunoregulatory capacity while repressing the differentiation programs of multiple effector lineages in CD4+ T cells. BACH2 was required for efficient formation of regulatory (Treg) cells and consequently for suppression of lethal inflammation in a manner that was Treg-cell-dependent. Assessment of the genome-wide function of BACH2, however, revealed that it represses genes associated with effector cell differentiation. Consequently, its absence during Treg polarization resulted in inappropriate diversion to effector lineages. In addition, BACH2 constrained full effector differentiation within TH1, TH2 and TH17 cell lineages. These findings identify BACH2 as a key regulator of CD4+ T-cell differentiation that prevents inflammatory disease by controlling the balance between tolerance and immunity.

1 January 2016 in Cell Metabolism
Verified
Journal Article
Closed access
MSMadhusudhanan Sukumar
Madhusudhanan Sukumar
JLJie Liu
Jie Liu
GMGautam U. Mehta
Gautam U. Mehta
SPShashank J. Patel
Shashank J. Patel
RRRahul Roychoudhuri
Rahul Roychoudhuri
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo